MindMed Initiates Phase 2a LSD Trial for the Treatment of Adult ADHD

Press/Media: ResearchPopular

Description

- Enrolling patients in proof-of-concept exploratory trial conducted in collaboration with the University Hospital Basel inSwitzerland ... concept exploratory trial conducted in collaboration with the University Hospital Basel inSwitzerlandandMaastricht Universityinthe ...

Period2 Nov 2021 → 20 Dec 2021

Media coverage

186

Media coverage

Keywords

  • 2a Trial Design
  • ADHD proof
  • ADHD trial
  • MindMed executive team
  • MindMed trades
  • MindMed's product candidates
  • Mindmed logo
  • POC trial
  • actual results
  • adults
  • broader comprehensive LSD
  • ADHD
  • adult patients
  • dose schedule
  • low-dose LSD
  • lysergic acid diethylamide
  • patient enrolment
  • phase 2a proof
  • placebo
  • treatment for ADHD in adults
  • trial
  • Global ADHD Therapeutics Market
  • MindMed’s research and development expenses
  • MindMed’s share price
  • POC clinical study
  • alcohol use disorder
  • annual growth rate
  • attention deficit hyperactivity disorder
  • behavioral and personality changes
  • changes in patients
  • LSD or placebo
  • extensive biopharmaceutical experience to MindMed
  • first site
  • higher score corresponds
  • impulsivity and hyperactivity
  • British American Tobacco
  • FORWARD-LOOKING STATEMENTS
  • HnB platform
  • Options vesting
  • Poda team
  • Poda's HnB system
  • analyses
  • expectations or statements
  • biggest tobacco
  • broad management experience
  • combustible smoking products